New england journal of medicine publishes positive phase 3 trial results for regen-cov™ (casirivimab and imdevimab) to prevent sars-cov-2 infection

Tarrytown, n.y., aug. 4, 2021 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the new england journal of medicine (nejm) published positive detailed results from a phase 3 trial that assessed the ability of regen-cov™ (casirivimab and imdevimab) to prevent covid-19 infection among household contacts of sars-cov-2 infected individuals.
REGN Ratings Summary
REGN Quant Ranking